The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
Cyr61 Expression Confers Resistance to Apoptosis in Breast Cancer MCF-7 Cells by a Mechanism of NF-κB-dependent XIAP Up-Regulation
Open accessAbstract
The aggressiveness of a tumor is partly attributed to its resistance to chemotherapeutic agent-induced apoptosis. Cysteine-rich 61 (Cyr61), from the CCN gene family, is a secreted and matrix-associated protein, which is involved in many cellular activities such as growth and differentiation. Here we established a cell model system to examine whether stable expression of Cyr61 in MCF-7 cells can confer resistance to apoptosis and identify possible participating mechanisms. We showed that stable cell lines overexpressing Cyr61 had acquired a remarkable resistance to apoptosis induced by paclitaxel, adriamycin, and β-lapachone. Most interesting, gel shift and reporter assays showed that the Cyr61-overexpressing cells had significantly increased NF-κB activity compared with neo control cells. Blockage of NF-κB activity in Cyr61-expressing cells by transfecting with a dominant negative (DN)-IκB or with an NF-κB decoy rendered them more susceptible to anti-cancer drugs-induced apoptosis. In addition, several NF-κB-regulated anti-apoptotic genes were examined, and we found that only XIAP showed a significant 3–4-fold increase in mRNA and protein in Cyr61-overexpressing cells but not in neo control cells. Treatment with inhibitor of apoptosis protein (XIAP)-specific antisense, but not sense, oligonucleotides abolished the apoptosis resistance of the Cyr61-overexpressing cells. At the same time, transfection of these stable cells with DN-IκB to block NF-κB activity also effectively reduced the elevated XIAP level. Function-neutralizing antibodies to αvβ3 and αvβ5 could inhibit Cyr61-mediated NF-κB activation as well as XIAP expression. Taken together, our data suggested that Cyr61 plays an important role in resistance to chemotherapeutic agent-induced apoptosis in human breast cancer MCF-7 cells by a mechanism involving the activation of the integrins/NF-κB/XIAP signaling pathway. The aggressiveness of a tumor is partly attributed to its resistance to chemotherapeutic agent-induced apoptosis. Cysteine-rich 61 (Cyr61), from the CCN gene family, is a secreted and matrix-associated protein, which is involved in many cellular activities such as growth and differentiation. Here we established a cell model system to examine whether stable expression of Cyr61 in MCF-7 cells can confer resistance to apoptosis and identify possible participating mechanisms. We showed that stable cell lines overexpressing Cyr61 had acquired a remarkable resistance to apoptosis induced by paclitaxel, adriamycin, and β-lapachone. Most interesting, gel shift and reporter assays showed that the Cyr61-overexpressing cells had significantly increased NF-κB activity compared with neo control cells. Blockage of NF-κB activity in Cyr61-expressing cells by transfecting with a dominant negative (DN)-IκB or with an NF-κB decoy rendered them more susceptible to anti-cancer drugs-induced apoptosis. In addition, several NF-κB-regulated anti-apoptotic genes were examined, and we found that only XIAP showed a significant 3–4-fold increase in mRNA and protein in Cyr61-overexpressing cells but not in neo control cells. Treatment with inhibitor of apoptosis protein (XIAP)-specific antisense, but not sense, oligonucleotides abolished the apoptosis resistance of the Cyr61-overexpressing cells. At the same time, transfection of these stable cells with DN-IκB to block NF-κB activity also effectively reduced the elevated XIAP level. Function-neutralizing antibodies to αvβ3 and αvβ5 could inhibit Cyr61-mediated NF-κB activation as well as XIAP expression. Taken together, our data suggested that Cyr61 plays an important role in resistance to chemotherapeutic agent-induced apoptosis in human breast cancer MCF-7 cells by a mechanism involving the activation of the integrins/NF-κB/XIAP signaling pathway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“CCN1 promotes the survival of endothelial cells through integrin αvβ3 [72], and inhibits apoptosis by activation of Akt in pulmonary epithelial cells [80] or upregulation of XIAP in MCF7 breast cancer cells [81].”
From CCN1/CYR61: the very model of a modern matricellular protein (2011) · cites this paper as [81]
In the citing paper
“Although CCN1 promotes cell survival in endothelial cells and some cancer cells [72,81], it represents the first example of an ECM molecule that can induce apoptosis through the process cell adhesion [61].”
From CCN1/CYR61: the very model of a modern matricellular protein (2011) · cites this paper as [81]
In the citing paper
“The anti-apoptotic functions of CCN1 in breast cancer cells are mediated through its receptor integrin αvβ3 [81,153], whose expression is also induced by CCN1 [154].”
From CCN1/CYR61: the very model of a modern matricellular protein (2011) · cites this paper as [81]
In the citing paper
“In MCF7 breast cancer cells, which are dependent on estrogen for growth, overexpression of CCN1 renders these cells estrogen-independent and significantly resistant to apoptosis, in part through upregulation of the anti-apoptotic protein XIAP [81,152,153].”
From CCN1/CYR61: the very model of a modern matricellular protein (2011) · cites this paper as [81]
In the citing paper
“In MCF7 breast cancer cells, which are dependent on estrogen for growth, overexpression of CCN1 renders these cells estrogen-independent and significantly resistant to apoptosis, in part through upregulation of the anti-apoptotic protein XIAP [81,152,153].”
From CCN1/CYR61: the very model of a modern matricellular protein (2011) · cites this paper as [81]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Chawla‐Sarkar, M., Bauer, J. A., Lupica, J. A., Morrison, B., Tang, Z., Oates, R. K., Almasan, A., DiDonato, J. A., Borden, E. C., & Lindner, D. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306111200 · Cited by 77
RetractedA multigenic program mediating breast cancer metastasis to bone
Kang, Y., Siegel, P. M., Shu, W., Drobnjak, M., Käkönen, S.-M., Cordon‐Cardo, C., Guise, T. A., & Massagué, J. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00132-6 · Cited by 2,605
Oxidative Stress and Stress-Activated Signaling Pathways: A Unifying Hypothesis of Type 2 Diabetes
Evans, J. L., Goldfine, I. D., Maddux, B. A., & Grodsky, G. M. (2002) · Endocrine Reviews · doi:10.1210/er.2001-0039 · Cited by 2,232
AP-1: a double-edged sword in tumorigenesis
Eferl, R., & Wagner, E. F. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1209 · Cited by 2,218
Lowe, S. W., & Lin, A. W. (2000) · Carcinogenesis · doi:10.1093/carcin/21.3.485 · Cited by 1,889
Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB
Baldwin, A. S. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11991 · Cited by 1,427
The inhibitors of apoptosis (IAPs) and their emerging role in cancer
LaCasse, E. C., Baird, S. D., Korneluk, R. G., & MacKenzie, A. (1998) · Oncogene · doi:10.1038/sj.onc.1202569 · Cited by 980
Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-β
Abreu, J. G., Ketpura, N. I., Reversade, B., & Robertis, E. M. D. (2002) · Nature Cell Biology · doi:10.1038/ncb826 · Cited by 901
Apoptosis and melanoma chemoresistance
Soengas, M. S., & Lowe, S. W. (2003) · Oncogene · doi:10.1038/sj.onc.1206454 · Cited by 836
To be, or not to be: NF-κB is the answer – role of Rel/NF-κB in the regulation of apoptosis
Kucharczak, J., Simmons, M. J., Fan, Y., & Gélinas, C. (2003) · Oncogene · doi:10.1038/sj.onc.1207230 · Cited by 773
Research works printed but not linked: 8
- O'Brien, 1990, Mol. Cell. Biol., 10, 3569
- Xie, 2001, Cancer Res., 61, 8917
- Romieu-Mourez, 2002, Cancer Res., 62, 6770
- Grzeszkiewicz, 2002, Endocrinology, 143, 1441, 10.1210/endo.143.4.8731 · DOI · Paper page
- Tsai, 2000, Cancer Res., 60, 5603
- Qi, 2003, Cancer Res., 63, 7076
- Kikuchi, 2003, Cancer Res., 63, 107
- Yang, 2003, Cancer Res., 63, 6815
Cited by
Sorted by citations
NF-κB activation as a pathological mechanism of septic shock and inflammation
Liu, S. F., & Malik, A. B. (2006) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00477.2005 · Cited by 769
Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets
Jun, J.-I., & Lau, L. F. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3599 · Cited by 568
Functions and mechanisms of action of CCN matricellular proteins
Chen, C.-C., & Lau, L. F. (2009) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.07.025 · Cited by 549
Expression Profiling Reveals Novel Pathways in the Transformation of Melanocytes to Melanomas
Hoek, K. S., Rimm, D. L., Williams, K. R., Zhao, H., Ariyan, S., Lin, A., Kluger, H. M., Berger, A. J., Cheng, E., Trombetta, E. S., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0731 · Cited by 494
YAP/TAZ Signaling and Resistance to Cancer Therapy
Nguyen, C. D. K., & Yi, C. (2019) · Trends in Cancer · doi:10.1016/j.trecan.2019.02.010 · Cited by 437
Metadata
- Authors
- Lin, M.-T., Chang, C.-C., Chen, S.-T., Chang, H.-L., Su, J.-L., Chau, Y.-P., & Kuo, M.-L.
- Affiliations
- National Taiwan University Hospital (TW)
- National Taiwan University (TW)
- National Health Research Institutes (TW)
- National Yang Ming University (TW)
- Corresponding author
- Kuo, Min-Liang
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2004-06
- Volume
- 279
- Issue
- 23
- Pages
- 24015-24023
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W1983777512
- Cited by
- 194
- References
- 86
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 5 · 2023: 4 · 2022: 12 · 2021: 9 · 2020: 5 · 2019: 5 · 2018: 8 · 2017: 9 · 2016: 10 · 2015: 8 · 2014: 8 · 2013: 9 · 2012: 11
- FWCI
- 4.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Science Council
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Connective Tissue Growth Factor Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
- Keywords
- CYR61, CCN family, apoptosis resistance, breast cancer, MCF-7 cells, NF-κB, XIAP, chemoresistance, integrins, integrin αvβ3, paclitaxel, doxorubicin, β-lapachone, antisense oligonucleotides, anti-apoptotic genes
- MeSH terms
- Antibiotics, Antineoplastic, Antineoplastic Agents, Phytogenic, Breast Neoplasms, Cell Division, Cell Nucleus, Cell Survival, DNA, Doxorubicin, Flow Cytometry, Genes, Dominant, Humans, Microscopy, Fluorescence, Models, Biological, Naphthoquinones, Promoter Regions, Genetic, Proteins, RNA, Messenger, Time Factors, Transfection, Blotting, Western, Signal Transduction, Up-Regulation, Integrins, NF-kappa B, Oligonucleotides, Antisense, Apoptosis, Paclitaxel, Immediate-Early Proteins, Genes, Reporter, Receptors, Vitronectin, Reverse Transcriptase Polymerase Chain Reaction, Active Transport, Cell Nucleus, Intercellular Signaling Peptides and Proteins, Integrin alphaVbeta3, Cell Line, Tumor, X-Linked Inhibitor of Apoptosis Protein, Cysteine-Rich Protein 61
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review